10-KPeriod: FY2020

Guardant Health, Inc. Annual Report, Year Ended Dec 31, 2020

Filed February 25, 2021For Securities:GH

Summary

Guardant Health, Inc.'s (GH) 10-K filing for the fiscal year ended December 31, 2020, highlights the company's operational and financial status as it continues to advance its precision oncology testing and development services. The company operates as a single reportable segment, indicating a unified business strategy. A significant portion of its financial assets are held in cash equivalents and marketable securities, providing a stable liquidity position. The filing details Guardant Health's revenue recognition policies under ASC 606, emphasizing the complexities in estimating variable consideration for clinical tests and milestone-based revenue for biopharmaceutical services. The company also discloses substantial investments in research and development, along with a significant increase in stock-based compensation, particularly related to market-based restricted stock units (MSUs) for executive compensation. The issuance of $1.15 billion in 0% Convertible Senior Notes in November 2020 is a key event, intended to fund operations and future growth, alongside hedging transactions to mitigate potential dilution. Financially, the company reported a net loss for the year, a common characteristic of growth-stage biotechnology companies investing heavily in innovation and market expansion. Key areas of focus for investors include the company's strong liquidity, ongoing investment in R&D, the strategic implications of its joint venture, and the potential impact of its convertible debt and stock-based compensation on future earnings and shareholder value.

Financial Highlights

53 data points
Beta

Revenue

$286.73M

Net Income

-$253.78M

-88.5% Net Margin

EPS (Diluted)

$-2.60

Total Assets

$2.27B

Cash & Equivalents

$832.98M

Free Cash Flow

-$140.10M

Financial Statements
Beta
Revenue$286.73M
R&D Expenses$149.86M
Operating Expenses$541.68M
Operating Income-$254.95M
Interest Expense$4.77M
Net Income-$253.78M
EPS (Basic)$-2.60
EPS (Diluted)$-2.60
Shares Outstanding (Basic)97.50M
Shares Outstanding (Diluted)97.50M

Key Highlights

  • 1Guardant Health operates as a single, reportable business segment, reflecting a cohesive operational strategy.
  • 2The company holds a substantial amount of cash and cash equivalents, alongside marketable securities, indicating strong liquidity and financial flexibility.
  • 3Guardant Health issued $1.15 billion in 0% Convertible Senior Notes due 2027, a significant financing event aimed at supporting future growth and operations.
  • 4Stock-based compensation expense increased significantly, driven by market-based restricted stock units (MSUs) granted to executives, impacting the company's overall expenses.
  • 5The company continues to invest heavily in Research and Development, which is crucial for its innovation pipeline in precision oncology.
  • 6Revenue recognition policies are detailed under ASC 606, highlighting the estimation of variable consideration and milestone payments, which require significant judgment.
  • 7The company has a joint venture with an affiliate of SoftBank, consolidating its financial results, which is key for global commercialization efforts.

Frequently Asked Questions

Guardant Health's primary business focus is on providing precision oncology testing services to physicians and biopharmaceutical customers, as well as offering biopharmaceutical research and development services. This includes genomic profiling and delivering genomic information derived from their platform.

The most significant financing activity was the issuance of $1.15 billion in 0% Convertible Senior Notes due 2027 in November 2020. This was accompanied by convertible note hedge transactions to mitigate potential dilution.

Guardant Health holds cash equivalents and marketable securities, primarily in high-grade U.S. government and agency securities and corporate bonds. These are classified as available-for-sale and recorded at fair value, with unrealized gains and losses recognized in accumulated other comprehensive income. The company invests to preserve principal, ensure liquidity, and achieve a competitive return.

Guardant Health recognizes revenue under ASC 606. For clinical customers, revenue from precision oncology tests is recognized when results are reported. Variable consideration, based on historical reimbursement data, requires significant estimation and judgment. For biopharmaceutical customers, revenue from development services is recognized over time using input methods, often tied to milestones which also involve significant estimation regarding their achievability.

Key expenses include cost of precision oncology testing, research and development, sales and marketing, general and administrative costs, and cost of development services. Investors should pay close attention to stock-based compensation, which was substantial and increased significantly in 2020 due to market-based restricted stock units (MSUs), impacting reported net income.